Immunovant Sciences GmbH
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO0%
Delay Index: of 7 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Immunovant Sciences GmbH on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| IMVT-1402 NCT06980805 |
P2 | Active, not recruiting | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | 56 | 2026-10 (-6 mo) |
| IMVT-1402 NCT07018323 |
P2 | Recruiting | Graves' Disease | 210 | 2027-05 |
| IMVT-1402 NCT06754462 |
P2 | Active, not recruiting | Rheumatoid Arthritis | 120 | 2027-09 |
| IMVT-1402 NCT07039916 |
P3 | Recruiting | Generalized Myasthenia Gravis | 231 | 2027-12 |
| IMVT-1402 NCT06727604 |
P2 | Recruiting | Graves' Disease | 240 | 2028-06 |
| IMVT-1402 NCT06979531 |
P2 | Active, not recruiting | Primary Sjögren's Syndrome | 180 | 2028-07 |
| Imeroprubart NCT07032662 |
P2 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy | 162 | 2028-08 |
| IMVT-1402 NCT07286006 |
P2 | Enrolling by invitation | Graves' Disease | 372 | 2030-03 |